Update on SCORED and SOLOIST Cardiovascular and Kidney - Outcomes Trials
In this medfyle
Expert commentary by Justin Echouffo Tcheugui, MD, PhD
This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.
Acknowledgements
This is a highlights summary of an oral session given at the ADA 2021 - 81st Scientific Sessions and presented by:
Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC, Brigham and Women's Hospital Heart and Vascular Center, Boston, MA, USA
Lawrence A. Leiter, MD, FRCPC, FACP, FACE, FAHA, FACC, University of Toronto, Toronto, Canada
Subodh Verma, MD, PhD, FRCSC, University of Toronto, Toronto, Canada
Mikhail N. Kosiborod, MD, Saint Luke's Mid America Heart Institute, University of Missouri-Kansas City, Kansas City, MO, USA
Julia B. Lewis, MD, Vanderbilt University Medical Center, Nashville, TN, USA
The content is produced by Infomedica, the official reporting partner of ADA 2021.
The presenting authors of the original session had no part in the creation of this conference highlights summary.
In addition, an expert commentary on the topic has been provided by:
Justin Echouffo Tcheugui, MD, PhD
Johns Hopkins University, Baltimore, Maryland, USA.
About the Expert
Justin Echouffo Tcheugui, MD, PhD
Johns Hopkins University, Baltimore, Maryland, USA.
Dr. Echouffo Tcheugui is Assistant Professor of Medicine & Epidemiology at Johns Hopkins University. His background is in clinical medicine, epidemiology and clinical investigation. As a clinical endocrinologist and physician-scientist, he shares his time between his clinical practice and his research. His clinical practice focuses on diabetes, obesity, and lipid disorders. His research interests include the investigation of approaches to prevent cardiovascular complications related to obesity and all forms of hyperglycemia (prediabetes, type 2 diabetes, gestational diabetes), with a special emphasis on the heart failure outcome. He also investigates the primary prevention and early detection of type 2 diabetes, which includes clinic- and population-based approaches.
Disclosures: nothing to disclose.
References
1. Connelly KA, Bhatt DL, Verma S. Can We DECLARE a Victory against Cardio-Renal Disease in Diabetes? Cell Metabolism 2018;28:813–5.
2. Rosenstock J, Cefalu WT, Lapuerta P, et al. Greater dose-ranging effects on A1C levels than on glucosuria with LX4211, a dual inhibitor of SGLT1 and SGLT2, in patients with type 2 diabetes on metformin monotherapy. Diabetes Care 2015;38:431–8.
